nimotuzumab
biocon,daiichi sankyo,oncoscience
['pancan', 'nimotuzumab', 'pancreatic']
anti-egrf antibody nimotuzumab (from china) added to gemcitabine shows activity in subset of pancreatic cancer about 10-20% of patients with kras wild-type tumors [#asco22 abstract lba4011] #pancan story to follow. 
Medscape Oncology provides breaking medical news, references for drugs, diseases, and procedures, and free CME.